Abstract Background and aims Heart failure with preserved ejection fraction (HFpEF) is a complex clinical phenotype often associated to the presence of multiple non-cardiac interrelated comorbidities including diabetes, obesity, hypertension. A major challenge in the development of new therapies for HFpEF is the lack of animal models that truly recapitulate the complexities of the disease. One promising candidate is the Lund MetS rat, a congenic BBDR.cg-lepr.cp model generated by introgression of the Koletsky leptin receptor mutation into the BioBreeding Diabetes Resistant (BBDR) rat. Methods 14-week-old Lund MetS obese T2D rats were exposed to salt enriched diet (0.8% NaCl in diet) for 6 weeks. Age-matched lean rats (ctrl) were fed a normal chow diet. Cardiovascular phenotyping was assessed by echocardiography and blood pressure measurement. Vascular function of isolated thoracic aortas, as well as kidney and cardiac parameters were also evaluated at the end of the 6-week diet period. Results After 6-week enriched salt diet period, mean arterial pressure increased from 120mmHg to 160mmHg (vs 100mmHg in chow-fed lean rat). The hypertensive state also led to renal hypertrophy with up to a 2-fold higher kidney weights. Echocardiography showed a preserved systolic function with quite similar ejection fraction and fractional shortening in Lund MetS and lean rats. In contrast, high salt-fed Lund MetS rats developed cardiac hypertrophy confirmed by a large increase in heart, left ventricle, and left atria weights as compared to lean rats. Diastolic dysfunction was also highlighted with inverted E/A and E'/A' ratios along with a prolongation of the isovolumic relaxation time (IVRT). This was accompanied by an increase in circulating levels of soluble ST2 and NT- proBNP. Finally, aortic rings assays showed that both endothelium dependent and independent vasodilating properties were impaired in the high salt-fed Lund MetS rats. Conclusions The present data demonstrate that the Lund MetS rat fed a high salt diet developed a marked hypertension, pathological cardiac remodeling and diastolic dysfunction without modification of ejection fraction, along with obesity and type 2 diabetes. Thus, this could be a relevant model to bring forward effective new treatments for HFpEF patients. Funding Acknowledgement Type of funding sources: None.